Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

被引：10

作者：

Gantner, Pierre ^{[1
,2
]}

Hessamfar, Mojgan ^{[3
]}

Souala, Mohamed Faouzi ^{[4
]}

Valin, Nadia ^{[5
]}

Simon, Anne ^{[6
]}

Ajana, Faiza ^{[7
]}

Bouvet, Elisabeth ^{[8
]}

Rouveix, Elisabeth ^{[9
]}

Cotte, Laurent ^{[10
]}

Bani-Sadr, Firouze ^{[11
]}

Hustache-Mathieu, Laurent ^{[12
]}

Lebrette, Marie-Gisele ^{[13
]}

Truchetet, Francois ^{[14
]}

Galempoix, Jean-Marie ^{[15
]}

Piroth, Lionel ^{[16
]}

Pellissier, Gerard ^{[17
]}

Muret, Patrice ^{[18
]}

Rey, David ^{[19
]}

机构：

[1] Strasbourg Univ, Hop Univ Strasbourg, Lab Mol Virol, Strasbourg, France

[2] Strasbourg Univ, INSERM, Strasbourg, France

[3] CHU Bordeaux, Hop St Andre, Serv Med Interne & Malad Infectieuses, Bordeaux, France

[4] CHU Pontchaillou, Serv Malad Infectieuses & Trop, Rennes, France

[5] Hop St Antoine, AP HP, Serv Malad Infectieuses & Trop, Paris, France

[6] Hop La Pitie Salpetriere, AP HP, Serv Med Interne & Immunol Clin, Paris, France

[7] Ctr Hosp Tourcoing, Serv Univ Malad Infectieuses & Voyageur, Tourcoing, France

[8] Hop Bichat Claude Bernard, AP HP, Serv Malad Infect, Paris, France

[9] Hop Ambroise Pare, AP HP, Serv Med Interne, Boulogne, France

[10] Hop Croix Rousse, Malad Infect & Trop, Lyon, France

[11] Hop Robert Debre, Unite Malad Infect & Trop, Reims, France

[12] Hop Jean Minjoz, Serv Malad Infect & Trop, Besancon, France

[13] Hop Tenon, AP HP, Serv Malad Infect & Trop, Paris, France

[14] Ctr Hosp Metz Thionville, Serv Dermatol, Metz, France

[15] Ctr Hosp Manchester, Serv Med Infect, Charleville Mezieres, France

[16] CHU Dijon, Dept Infectiol, Dijon, France

[17] Grp Etud Risque Exposit Soignants Agents Infectie, Paris, France

[18] Hop Jean Minjoz, INSERM, Lab Pharmacol Clin, Besancon, France

[19] Hop Univ Strasbourg, HIV Infect Care Ctr, Le Trait Union, Strasbourg, France

来源：

CLINICAL INFECTIOUS DISEASES | 2020年 / 70卷 / 05期

关键词：

HIV; postexposure prophylaxis; completion; adherence; adverse events; DISOPROXIL FUMARATE; HIV; ADHERENCE;

D O I：

10.1093/cid/ciz577

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.

引用

页码：943 / 946

页数：4

共 50 条

[1] Single-tablet regimen with elvitegravir, cobicistat, emtricitabine and tenofovir for the treatment of early HIV infection
Teira, Ramon
Galindo, Maria
Montero, Marta
Portilla, Raquel
Ferrer, Ana
Martinez, Elisa
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[2] An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
Giacomet, Vania
Cossu, Maria V.
Capetti, Amedeo F.
Zuccotti, GianVincenzo
Rizzardini, Giuliano
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (03) : 269 - 276
[3] Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims
Malinverni, Stefano
Bedoret, Floriane
Bartiaux, Magali
Gilles, Christine
De Wit, Stephane
Libois, Agnes
[J]. SEXUALLY TRANSMITTED INFECTIONS, 2021, 97 (05) : 329 - 333
[4] Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen
Brown, Kimberley
Thomas, David
McKenney, Kevin
Reeder, Michael
Simonson, Richard Bruce
Bicer, Ceyhun
Nettles, Richard E.
Crauwels, Herta
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 541 - 548
[5] Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected
Gallant, Joel
Brunetta, Jason
Crofoot, Gordon
Benson, Paul
Mills, Anthony
Brinson, Cynthia
Oka, Shinichi
Cheng, Andrew
Garner, Will
Fordyce, Marshall
Das, Moupali
McCallister, Scott
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (03) : 294 - 298
[6] Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen
Rizzardini, Giuliano
Gori, Andrea
Miralles, Celia
Olalla, Julian
Molina, Jean-Michel
Raffi, Francois
Kumar, Princy
Antinori, Andrea
Ramgopal, Moti
Stellbrink, Hans-Jurgen
Das, Moupali
Chu, Hoa
Ram, Renee
Garner, Will
Shao, Yongwu
Chuck, Susan K.
Piontkowsky, David
Haubrich, Richard H.
[J]. AIDS, 2019, 33 (10) : 1583 - 1593
[7] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
Devred, Ines
Kayembe, Kick
Valin, Nadia
Rougier, Hayette
Shinga, Bruce Wuembulua
Lambert-Niclot, Sidonie
Chiarabini, Thibault
Meyohas, Marie-Caroline
Lacombe, Karine
[J]. BMC INFECTIOUS DISEASES, 2023, 23 (01)
[8] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
Inès Devred
Kick Kayembe
Nadia Valin
Hayette Rougier
Bruce Wuembulua Shinga
Sidonie Lambert-Niclot
Thibault Chiarabini
Marie-Caroline Meyohas
Karine Lacombe
[J]. BMC Infectious Diseases, 23
[9] Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1
Negredo, Eugenia
Clotet, Bonaventura
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 929 - 934
[10] Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens
Mayer, Kenneth H.
Jones, Daniel
Oldenburg, Catherine
Jain, Sachin
Gelman, Marcy
Zaslow, Shayne
Grasso, Chris
Mimiaga, Matthew J.
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (05) : 535 - 539

← 1 2 3 4 5 →